Report
Valens Research

LVGO - Embedded Expectations Analysis - 2020 09 02

Livongo Health, Inc. (LVGO:USA) currently trades above historical averages relative to UAFRS-based (Uniform) earnings, with a 166.3x Uniform P/E. At these levels, the market has bullish expectations for the firm, but management may be concerned about running at a net loss, Teladoc merger benefits, and the usefulness of their diabetes studies

Specifically, management may lack confidence in their ability to generate a net profit, sustain Adjusted EBITDA growth, and continue generating contract wins. In addition, they may be exaggerating the innovation benefits of the merger with Teladoc and they may have concerns maintaining their current cash balance. Moreover, management may lack confidence in their ability to replicate the positive financial ROI of their diabetes studies
Underlying
Livongo Health

Livongo Health is engaged in Applied Health Signals, which is involved in the management of chronic conditions. The company's platform provides cellular-connected devices, supplies, informed coaching, and data science-enabled insights and facilitates access to medications across multiple chronic conditions. The company provides the following solutions: Livongo for diabetes; Livongo for hypertension; Livongo for prediabetes and weight management; and Livongo for behavioral health by myStrength.

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch